| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Natalia Chamorro-Pareja, Alexander T Faje, Karen K Mille. The Risk of Adrenal Insufficiency after Treatment with Relatlimab in Combination with Nivolumab is Higher than Expected. The Journal of clinical endocrinology and metabolism. 2025-02-26. PMID:40001294. |
adrenal insufficiency from hypophysitis is a complication of immune checkpoint inhibitor (ici) therapy. |
2025-02-26 |
2025-02-28 |
Not clear |
| Akiko Nakazawa, Kei Shimada, Takuya Hashimot. [A Case of Anterior Pituitary Hypofunction and Central Diabetes Insipidus That Occurred after the Extended Right Hepatectomy for Cystic Duct Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. vol 51. issue 13. 2025-02-14. PMID:39948950. |
hypophysitis causes a decrease in hormone secretion ability in the area of inflammation, and in this case, vomiting occurred due to secondary adrenal insufficiency caused by anterior pituitary hypofunction, and polyuria occurred due to posterior pituitary dysfunction. |
2025-02-14 |
2025-02-16 |
Not clear |
| Verena Theiler-Schwetz, Christian Trummer, Lisa Schmitt, Angelika Terbuch, Barbara Obermayer-Pietsch, Erika Richtig, Stefan Pil. High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial. Annals of medicine. vol 57. issue 1. 2025-01-25. PMID:39862267. |
one of the most severe endocrine side effects of immune checkpoint inhibitors (ici) is hypophysitis leading to adrenal insufficiency. |
2025-01-25 |
2025-01-28 |
Not clear |
| Silvia Rossi, Francesca Silvetti, Monia Bordoni, Alessandro Ciarloni, Gianmaria Salvio, Giancarlo Balerci. Pembrolizumab-induced Thyroiditis, Hypophysitis and Adrenalitis: A Case of Triple Endocrine Dysfunction. JCEM case reports. vol 2. issue 11. 2024-11-05. PMID:39498471. |
subsequently the patient developed central adrenal insufficiency due to probable hypophysitis, and steroid replacement therapy was started. |
2024-11-05 |
2024-11-07 |
Not clear |
| Ludovico Di Gioia, Giovanni Dambrosio, Angelo Cignarelli, Annalisa Natalicchio, Sebastio Perrini, Luigi Laviola, Francesco Giorgino, Gian Pio Soric. From cortisol-producing adrenal adenoma to atrial myxoma, through nivolumab-induced hypophysitis: a complicated case report of Carney Complex. Endocrine. 2024-09-01. PMID:39217593. |
from cortisol-producing adrenal adenoma to atrial myxoma, through nivolumab-induced hypophysitis: a complicated case report of carney complex. |
2024-09-01 |
2024-09-04 |
Not clear |
| Fatima Abdullah AlRubaish, Nisha Gupta, Meng Zhu Shi, Stavroula Christopoulo. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism. BMJ case reports. vol 17. issue 5. 2024-05-21. PMID:38772867. |
she finally developed secondary adrenal insufficiency and was started on hydrocortisone replacement 4 weeks thereafter.this report highlights a case of immunotherapy-related hypophysitis with well-documented transient central hypercortisolism followed, within weeks, by profound secondary adrenal insufficiency. |
2024-05-21 |
2024-05-27 |
Not clear |
| Emmanouil Panagiotou, Sofia Ntouraki, Ioannis A Vathiotis, Maria Effrosyni Livanou, Athanasios Trimis, Georgios Evangelou, Andriani Charpidou, Konstantinos Syrigos, Melpomeni Pepp. Endocrine Immune-Related Adverse Events Are Independent Predictors of Survival in Patients with Lung Cancer. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730716. |
e-iraes presented at a median time of 4.1 months and included hypothyroidism (15.6%), hyperthyroidism (4.3%), adrenal insufficiency (0.4%), hypophysitis (0.4%), and diabetes mellitus (0.2%). |
2024-05-13 |
2024-05-27 |
Not clear |
| Sai-Ching Jim Yeung, Aiham Qdaisat, Jason J Bischof, Jeffrey M Caterino, Demetrios N Kyriacou, Christopher Coyne M. A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors. The American journal of emergency medicine. 2024-05-05. PMID:38705758. |
a case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors. |
2024-05-05 |
2024-05-08 |
Not clear |
| Hiroshi Iesaka, Hiraku Kameda, Aika Miya, Hiroshi Nomoto, Kyu Yong Cho, Akinobu Nakamura, Takashige Abe, Nobuo Shinohara, Tatsuya Atsum. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report. Medicine. vol 102. issue 51. 2023-12-22. PMID:38134115. |
this case report may provide useful insight to understanding the etiology of ici-induced hypophysitis, a severe irae leading to potentially fatal secondary adrenal insufficiency. |
2023-12-22 |
2023-12-25 |
Not clear |
| Ashen Fernando, Aastha Mittal, Rashid Cheem. Nothing Great Comes Without Its Risks: A Rare Case of Pembrolizumab-Induced Hypophysitis. JCEM case reports. vol 2. issue 1. 2023-12-20. PMID:38116159. |
reported endocrinopathies include thyroid dysfunction, insulin-deficient diabetes mellitus, primary adrenal insufficiency, and hypophysitis. |
2023-12-20 |
2023-12-23 |
Not clear |
| Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, Yinglai Huan. Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis abnormalities: a clinical case. Endocrine oncology (Bristol, England). vol 2. issue 1. 2023-07-12. PMID:37435468. |
two important lessons may be gleaned from this case: (i) ssts can be normal in early cases of secondary adrenal insufficiency, for example, hypophysitis due to adrenal reserve and (ii) when there is mismatch between the clinical and biochemical presentation, the acth should be repeated using a different assay. |
2023-07-12 |
2023-08-14 |
Not clear |
| Joshua K Salabei, Dhaval Upadhyay, Sripal A Pada. Induction of Hypopituitarism Following Ipilimumab/Nivolumab Therapy Followed by Radiation in the Treatment of Metastatic Scalp Melanoma. HCA healthcare journal of medicine. vol 2. issue 5. 2023-07-10. PMID:37425126. |
pituitary dysfunction (hypophysitis) leading to secondary adrenal insufficiency, or primary adrenal insufficiency caused by immune checkpoint inhibitors, have been documented. |
2023-07-10 |
2023-08-14 |
Not clear |
| Simona Coniac, Mariana Cristina Costache Outas, Edvina-Elena Pirvu, Raluca-Ileana Patru, Estera Gainariu, Ciprian Aldea, Polixenia Georgeta Iorga, Mihaela Ambroci, Horia-Dan Liscu, Andreea-Iuliana Miron, Corin Badi. Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy-Retrospective Study from a Tertiary-Level Hospital in Romania. Diagnostics (Basel, Switzerland). vol 13. issue 10. 2023-05-27. PMID:37238273. |
from this cohort, 109 nsclc patients qualified for baseline endocrine estimation and 13 patients (11.9%) developed endocrine iraes, such as hypophysitis (4.5%), thyroid disorder (5.5%) and primary adrenal insufficiency (1.8%), with one or more endocrine glands being affected. |
2023-05-27 |
2023-08-14 |
Not clear |
| Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti, Anupam Kotwa. TEST ARTICLE: Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. Journal of the National Comprehensive Cancer Network : JNCCN. 2023-04-11. PMID:37041011. |
test article: hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival. |
2023-04-11 |
2023-08-14 |
Not clear |
| Frédérique Albarel, Thierry Brue, Frédéric Castinett. Pituitary and adrenal disorders induced by immune checkpoint inhibitors. Annales d'endocrinologie. 2023-03-25. PMID:36965852. |
french guidelines on immunotherapy-related endocrine iraes were published in 2018, with a specific algorithm for hypophysitis and primary adrenal insufficiency (pai), based on clinical suspicion followed by biochemical and imaging evaluation, and are still relevant today. |
2023-03-25 |
2023-08-14 |
Not clear |
| Frédérique Albarel, Thierry Brue, Frédéric Castinett. Pituitary and adrenal disorders induced by immune checkpoint inhibitors. Annales d'endocrinologie. 2023-03-25. PMID:36965852. |
here we present the general pathophysiological mechanisms of these toxicities, and discuss the incidence, diagnosis, treatment, progression, management and monitoring of pituitary and adrenal disorders in patients treated by immunotherapy, with emphasis on hypophysitis, which is much more frequent than pai with this type of molecule. |
2023-03-25 |
2023-08-14 |
Not clear |
| Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti, Anupam Kotwa. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. Journal of the National Comprehensive Cancer Network : JNCCN. 2023-02-24. PMID:36828029. |
hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival. |
2023-02-24 |
2023-08-14 |
Not clear |
| Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V Karamouzi. Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers. vol 15. issue 2. 2023-01-21. PMID:36672324. |
endocrine dysfunctions can manifest as hypophysitis, thyroid dysfunction, hypoparathyroidism, insulin-deficient diabetes mellitus, and primary adrenal insufficiency. |
2023-01-21 |
2023-08-14 |
human |
| Xinyu Shen, Minglan Yang, Hua Xu, Huan Zhou, Liwei Wang, Jing M. Immunotherapy-Associated Hypophysitis Under Anti-PD1: Two Case Reports. Endocrine, metabolic & immune disorders drug targets. 2022-12-12. PMID:36503448. |
he was diagnosed with adrenal insufficiency secondary to immunotherapy-associated hypophysitis and received a physiological dose of glucocorticoids. |
2022-12-12 |
2023-08-14 |
human |
| Benjamin C Park, Seungyeon Jung, Jordan J Wright, Douglas B Johnso. Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge. The oncologist. 2022-10-26. PMID:36288471. |
a 33-year-old woman with recurrent metastatic melanoma with adrenal, pelvic, and inguinal metastases developed recurrent hypophysitis during treatment with ipilimumab and nivolumab which recurred with rechallenge >5 years later. |
2022-10-26 |
2023-08-14 |
Not clear |